Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.67 |
| ▸ | CTSC | P53634 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174322 | 1.00 | MME (0.67) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL8525810 | 1.00 | MME (0.67) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL29543743 | 0.95 | MME (0.61) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL30735658 | 0.93 | OPRD1 (0.62) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL31215109 | 0.93 | OPRD1 (0.62) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL1711844 | 0.92 | MME (0.58) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL29377179 | 0.92 | MME (0.57) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL31215083 | 0.91 | OPRD1 (0.60) | MMECTSCOPRM1OPRD1 | |
| SCHEMBL29351955 | 0.91 | CTSD (0.57) | MMECTSCALPIPKMPTGS1 | |
| SCHEMBL30974432 | 0.90 | MME (0.56) | MMECTSCOPRM1OPRD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099867-A1 | SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-15 | — | — | WO | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | claimed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | claimed |
| CN-121426896-B | Glycopeptide for improving sleep and application thereof | 长春中医药大学附属医院(吉林省中医院) | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099867-A1 | SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-15 | — | — | WO | disclosed |
| US-20260109757-A1 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION | SCHOLAR ROCK INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| CN-114224908-A | Application of cordyceps militaris polysaccharide in preparation of product for regulating intestinal flora and metabolite disorder caused by high-fat diet | 暨南大学 | 2022-03-25 | — | — | CN | disclosed |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-107158398-B | Polymer-conjugated MetAP2 inhibitors and methods of treatment using the same | 辛德弗雷克斯公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-3947426-A1 | GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE | The General Hospital Corporation (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | MME 1391/4885CTSC 6/4885ALPI 1142/4885 |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | MME 1189/4885CTSC 26/4885ALPI 3061/4885 |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 49/4885CTSC 500/4885ALPI 1972/4885 |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | MME 2720/4885CTSC 1548/4885ALPI 2489/4885 |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 200/4885CTSC 707/4885ALPI 1955/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | MME 4413/4885CTSC 2720/4885ALPI 276/4885 |
| US-20260109757-A1 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION | TGFBR1, TGFBR2, IGF2BP3 | MME 2218/4885CTSC 786/4885ALPI 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.